Are you Dr. Cohen?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 42 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5777 E Mayo Blvd
Phoenix, AZ 85054Phone+1 480-342-4800Fax+1 602-301-8572
Summary
- Dr. Peter Cohen, MD is an oncologist in Phoenix, Arizona. He is currently licensed to practice medicine in Arizona, Ohio, and Maryland. He is affiliated with Mayo Clinic Hospital.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Geisel School of Medicine at DartmouthClass of 1979
Certifications & Licensure
AZ State Medical License 2008 - 2022
OH State Medical License 1998 - 2009
MD State Medical License 1989 - 1998- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 101 citationsDetection of occult follicular lymphoma by specific DNA amplification.M Stetlet-Stevenson, Mark Raffeld, Peter A. Cohen, Jeffrey Cossman
Blood. 1988-11-01 - 646 citationsIntracellular oxidation-reduction states in vivo.Britton Chance, Peter A. Cohen, Frans F. Jöbsis, Brigitte Schoener
Science. 1962-08-17 - 39 citationsInhibition of Adaptive Immunity by IL9 Can Be Disrupted to Achieve Rapid T-cell Sensitization and Rejection of Progressive Tumor ChallengesDominique B. Hoelzinger, Ana Lucia Dominguez, Peter A. Cohen, Sandra J. Gendler
Cancer Research. 2014-12-01
Press Mentions
Researchers Find Cancer-Fighting Drugs Help Morbidly Obese Mice Lose WeightJanuary 17th, 2017
Grant Support
- Sunitinib Modulation Of Cancer ImmunotherapyNational Cancer Institute2010–2012
- Role Of Macrophage Regulatory Cells (Mac-Regs) In Immune RegulationNational Institute Of Allergy And Infectious Diseases2011
- Optimized Ex Vivo Expansion Of Anti-Tumor TH1 And TC1 For Adoptive Immunotherapy.National Cancer Institute2009–2010
- Proliferative Conditioning Of Tumor-Competent Dendritic Cell PrecursorsNational Cancer Institute2008–2010
- Proliferative Conditioning Of Tumor-Competent Dendritic Cell PrecursorsNational Cancer Institute2007–2008
- CD8+ Helper-Independent T Cells In Tumor TherapyNational Cancer Institute2004–2007
- CD8+ Helper Independent T Cells In Tumor TherapyNational Cancer Institute2001–2003
Professional Memberships
- Member
